ClinicalTrials.gg
Active, not recruitingNCT04514653AAVIATEUpdated Nov 17, 2026

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 2 interventional study of Ranibizumab and ABBV-RGX-314 Dose 1 in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by AbbVie. Active, not recruiting at 18 sites in United States. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Macular Degeneration by AbbVie — 3 open to participants now, 6 under way, 3 of them phase 3. Macular Degeneration · AbbVie.

Enrollment
9th of 22
146 · median 122
Started
2020
with 1 other
Phase 2
12 of 22
1 open now
Registered
17th of 22
by date

Among the 22 studies in Macular Degeneration by AbbVie, this one is the 9th largest by enrollment, is one of 2 that started in 2020, is one of 12 in phase 2, and was the 17th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 22 studies in Macular Degeneration by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Degeneration by AbbVie, or all of them as a file.
02

Study summary

This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® injections.

The duration of this study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314 after week 52, up to 80 weeks post-randomization.

The primary outcome measure for this investigational study is to evaluate the mean change in best-corrected visual acuity (BCVA) for ABBV-RGX-314 compared with ranibizumab monthly at the Week 40 visit.

Read the detailed description

This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety and tolerability of ABBV-RGX-314 gene therapy in subjects with nAMD.

ABBV-RGX-314 will be injected into the SCS part of the eye. Approximately 140 participants who meet the inclusion/exclusion criteria will be enrolled into one of 7 cohorts. Participants will be randomized in Cohorts 1 and 2 to receive ABBV-RGX-314 or the intravitreal ranibizumab control. Participants enrolled in Cohorts 3 through 5 will receive ABBV-RGX-314. Participants enrolled in Cohort 6 will receive ABBV-RGX-314 and will be randomized to one of two different post-procedural steroid regimens. Participants randomized in Cohort 7 will receive ABBV-RGX-314 with a protocol mandated steroid regimen or the intravitreal ranibizumab control. Cohort 1 will evaluate ABBV-RGX-314 Dose 1, Cohorts 2 and 3 will evaluate ABBV-RGX-314 Dose 2, Cohorts 4, 5, and 6 will evaluate ABBV-RGX-314 Dose 3, and Cohort 7 will evaluate ABBV-RGX-314 Dose 4.

The duration of the study will be up to 52 weeks or for ranibizumab control participants who cross over to ABBV-RGX-314, up to 80 weeks post-randomization.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)

Keywords

  • AMD
  • wet AMD
  • wAMD
  • nAMD
04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >/= 50 and \</= 89
  • Diagnosis of CNV secondary to age-related macular degeneration in the study eye.
  • Participants must have demonstrated a meaningful response to anti-VEGF therapy.
  • Willing and able to provide written, signed for this study.

Exclusion criteria

Exclusion Criteria:

  • CNV or macular edema in the study eye secondary to any causes other than AMD.
  • Subfoveal fibrosis or atrophy in study eye.
  • Participants who have had a prior vitrectomy.
  • Active or history of retinal detachment in the study eye.
  • History of intravitreal therapy in the study eye, such as intravitreal injection or product (IP), other than anti-VEGF therapy, in the 6 months prior to study entry.
  • Received any gene therapy.
  • Any condition preventing visualization of the fundus or VA improvement in the study eye, eg, cataract.
  • History of intraocular surgery in the study eye within 12 weeks of study entry.
  • Receipt of any IP within 30 days of study entry or 5 half-lives of the IP.
  • Myocardial infarction, cerebrovascular accident, or within 6 months of study entry.
  • Cohorts 1 - 5 only: Uncontrolled glaucoma in the study eye.

COHORT 6 AND 7 ONLY:

  • Active or history of glaucoma or ocular hypertension (steroid-induced ocular hypertension (Cohort 7 only)) in the study eye.
  • Certain OCT characteristics including: Large Pigment Epithelial Detachments (PED), Epiretinal Membrane (ERM) in the study eye at Visit 1.

Note: Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
146 participants (actual)

Study arms

  • Active comparator
    Ranibizumab control

    Control treatment arm

    Biological: Ranibizumab

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 1)

    ABBV-RGX-314 Dose 1

    Genetic: ABBV-RGX-314 Dose 1

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 2)

    ABBV-RGX-314 Dose 2

    Genetic: ABBV-RGX-314 Dose 2

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 3)

    ABBV-RGX-314 Dose 3

    Genetic: ABBV-RGX-314 Dose 3

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 3) and Local Steroid

    ABBV-RGX-314 Dose 3 and Local Steroid

    Genetic: ABBV-RGX-314 Dose 3 · Drug: Local Steroid

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 3) and Topical Steroid

    ABBV-RGX-314 Dose 3 and Topical Steroid

    Genetic: ABBV-RGX-314 Dose 3 · Drug: Topical Steroid

  • Experimental
    ABBV-RGX-314 Treatment Arm (Dose 4) and Topical Steroid

    ABBV-RGX-314 Dose 4 and Topical Steroid

    Drug: Topical Steroid · Genetic: ABBV-RGX-314 Dose 4

Interventions

  • BiologicalRanibizumab

    Ranibizumab (anti-VEGF agent)

  • GeneticABBV-RGX-314 Dose 1

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

    Also known as: Combination Product

  • GeneticABBV-RGX-314 Dose 2

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

    Also known as: Combination Product

  • GeneticABBV-RGX-314 Dose 3

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

    Also known as: Combination Product

  • DrugLocal Steroid

    Local steroid

  • DrugSteroidsStudies of SteroidsSteroids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Topical steroid

  • GeneticABBV-RGX-314 Dose 4

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)

    Also known as: Combination Product

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score

    The scale used is the early treatment diabetic retinopathy study (ETDRS) letter score from 0-100 and higher score being better vision.

    Time frame: 40 weeks

Secondary outcomes

  1. Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs)

    Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 52 weeks

  2. Vector shedding analysis in serum, urine, and tears

    Evaluate the safety and tolerability of ABBV-RGX-314

    Time frame: 52 Weeks

  3. Proportion of participants who experience ocular inflammation following SCS ABBV-RGX-314 administration

    To evaluate the incidences of ocular inflammation following SCS ABBV-RGX-314 administration

    Time frame: 52 weeks

  4. Mean change from baseline in choroidal neovascularization (CNV) lesion size and leakage area based on fluorescein angiography (FA)

    To evaluate the effect of ABBV-RGX-314 on CNV lesion growth and leakage as measured by FA

    Time frame: Up to Week 80

  5. Mean change from baseline in BCVA based on ETDRS score

    Evaluate the effect of ABBV-RGX-314 on BCVA

    Time frame: Up to Week 80

  6. Proportion of participants (1) gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 letters; (2) losing ≥ 15, ≥ 10, ≥ 5, or > 0 letters (3) maintaining vision (not losing ≥ 15 letters) compared with baseline as per BCVA

    To evaluate the effect of ABBV-RGX-314 on BCVA

    Time frame: Up to Week 52

  7. Mean change from baseline in CRT as measured by SD-OCT

    To evaluate the effect of ABBV-RGX-314 on CRT, as measured by SD-OCT

    Time frame: Up to Week 80

  8. Mean supplemental anti-VEGF injection annualized rate in the ABBV-RGX-314 treatment arms

    To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment

    Time frame: Up to Week 80

  9. Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate

    Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate through Week 40 and Week 52 compared with the prior 52 weeks preceding the first intravitreal ranibizumab injection received as part of the Screening Period (ABBV-RGX-314 administered participants)

    Time frame: 52 Weeks

  10. Proportion of participants with 0, ≤ 1, and ≤ 2 supplemental injections

    To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment

    Time frame: Up to Week 80

  11. Mean percent reduction in supplemental anti-VEGF injection annualized rate

    To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment

    Time frame: Up to Week 80

  12. Time from ABBV-RGX-314 administration to first supplemental anti-VEGF injection

    To assess the need for supplemental anti-VEGF therapy in participants who receive ABBV-RGX-314 treatment

    Time frame: 80 Weeks

  13. Aqueous humor ABBV-RGX- 314 TP concentration over time

    To evaluate the concentration of ABBV-RGX-314 TP in aqueous humor and serum

    Time frame: 52 Weeks

  14. Mean change from baseline in serum ABBV-RGX-314 TP concentration over time

    To evaluate the concentration of ABBV-RGX-314 TP in aqueous humor and serum

    Time frame: 80 Weeks

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Oct 2026, 73 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 73 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 17, 2020
StartActual
Aug 25, 2020
Primary completionActual
Oct 13, 2026was Aug 2026
CompletionEst.
Feb 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Oct 13, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Aug 2026→Oct 13, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04514653
Lead sponsor
AbbVie
Collaborators
REGENXBIO Inc.
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 25, 2020
Primary completion
Oct 13, 2026
Completion
Feb 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Steroids

Start the discussion